Stephanoascus ciferrii Complex: The Current State of Infections and Drug Resistance in Humans

Terenzio Cosio,Francesca Pica,Carla Fontana,Enrico Salvatore Pistoia,Marco Favaro,Isabel Valsecchi,Nikkia Zarabian,Elena Campione,Françoise Botterel,Roberta Gaziano
DOI: https://doi.org/10.3390/jof10040294
2024-04-18
Journal of Fungi
Abstract:In recent years, the incidence of fungal infections in humans has increased dramatically, accompanied by an expansion in the number of species implicated as etiological agents, especially environmental fungi never involved before in human infection. Among fungal pathogens, Candida species are the most common opportunistic fungi that can cause local and systemic infections, especially in immunocompromised individuals. Candida albicans (C. albicans) is the most common causative agent of mucosal and healthcare-associated systemic infections. However, during recent decades, there has been a worrying increase in the number of emerging multi-drug-resistant non-albicans Candida (NAC) species, i.e., C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. auris, and C. ciferrii. In particular, Candida ciferrii, also known as Stephanoascus ciferrii or Trichomonascus ciferrii, is a heterothallic ascomycete yeast-like fungus that has received attention in recent decades as a cause of local and systemic fungal diseases. Today, the new definition of the S. ciferrii complex, which consists of S. ciferrii, Candida allociferrii, and Candida mucifera, was proposed after sequencing the 18S rRNA gene. Currently, the S. ciferrii complex is mostly associated with non-severe ear and eye infections, although a few cases of severe candidemia have been reported in immunocompromised individuals. Low susceptibility to currently available antifungal drugs is a rising concern, especially in NAC species. In this regard, a high rate of resistance to azoles and more recently also to echinocandins has emerged in the S. ciferrii complex. This review focuses on epidemiological, biological, and clinical aspects of the S. ciferrii complex, including its pathogenicity and drug resistance.
microbiology,mycology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is about the current status of the **Stephanoascus ciferrii complex** (including *S. ciferrii*, *Candida allociferrii*, and *Candida mucifera*) in human infections and its resistance to antifungal drugs. Specifically, the paper focuses on the following aspects: 1. **Epidemiological characteristics**: Explore the global distribution of the S. ciferrii complex and its frequency as a pathogen of human infections. 2. **Biological characteristics**: Describe the morphological characteristics, growth conditions, and identification methods of the S. ciferrii complex, as well as its differences from other similar fungi. 3. **Clinical manifestations**: Summarize the clinical manifestations of human infections caused by the S. ciferrii complex, including local infections (such as ear and eye infections) and systemic infections (such as candidemia). 4. **Antifungal drug resistance**: Analyze the sensitivity of the S. ciferrii complex to existing antifungal drugs, especially its resistance to azole and echinocandin drugs. Through comprehensive research in these aspects, the paper aims to improve the understanding of S. ciferrii complex infections, so as to better manage and treat such infections, especially in the context of the increasing multi - drug resistance.